BERENICE TARIN: Open Payments
NPI 1740960905 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,846 in 200 payments from 33 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $5,846
Food & beverage: $5,799Education: $47
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 45 | $686 |
| Neurocrine BioSciences, Inc. | 16 | $363 |
| Alexion Pharmaceuticals, Inc. | 7 | $335 |
| UCB, Inc. | 14 | $333 |
| JAZZ PHARMACEUTICALS INC. | 6 | $306 |
| ARGENX US, INC. | 8 | $285 |
| Novartis Pharmaceuticals Corporation | 5 | $256 |
| Otsuka America Pharmaceutical, Inc. | 12 | $252 |
| HARMONY BIOSCIENCES LLC | 6 | $251 |
| Neurelis, Inc. | 9 | $215 |
Products named: INGREZZA, REXULTI, ULTOMIRIS, UBRELVY, QULIPTA, EPIDIOLEX, KESIMPTA, VALTOCO.
Industry payments across TX — which companies pay providers there.
